Market Overview

HIV/Aids Patient Groups Perspective of Corporate Reputation of Pharma Companies, 2017-2018: Patient Groups are Still Discontented with Pharma - ResearchAndMarkets.com

Share:

The "The
Corporate Reputation of Pharma Companies, 2017 - The Patient Perspective
of 74 HIV/Aids Patient Groups - HIV/Aids Edition"
report has
been added to ResearchAndMarkets.com's offering.

Still discontented with pharma...

  • The views of 74 HIV/AIDS patient groups.
  • Drawn from a November 2017-February 2018 survey.

HIV/AIDS patient groups have been among the most forthright and active
elements of the patient movement since the days of the founding of the
very first of them. Yet, despite the significant improvements in
HIV/AIDS treatments made over the decades, feelings of discontent among
HIV/AIDS patient groups still exist.

The 2017 Corporate-Reputation survey found HIV/AIDS patient groups to be
especially critical of the progress that the pharmaceutical industry may
(or may not) have made on a whole set of issues, including:

  • Integrity
  • Transparency in the sharing of clinical-trials data
  • Patient safety

Underlying these negative sentiments was a real feeling among HIV/AIDS
patient groups that people living with HIV/AIDS were increasingly
desperate for new products capable of providing a tangible difference to
their lives, delivering:

  • Higher potencies in drugs
  • Reduced side effects
  • Once-daily dosages; and
  • Less drug resistance.

On the topic of the industry's ability to innovate in the area of
HIV/AIDS, only 46% of the HIV/AIDS patient groups thought pharma to be
Excellent or Good in 2017. To put such a finding in context, 74% of
patient groups specialising in haemophilia saw the pharma industry as
Excellent or Good at innovating in the subject area of haemophilia in
2017.

In fact, as few as 31% of 2017's respondent HIV/AIDS patient groups
thought that the pharmaceutical industry had an Excellent or Good
corporate reputation that year, a figure well below the 44% reported by
HIV/AIDS patient groups in the 2016 survey, and also below the
equivalent figure from patient groups therapy wide (43%) in 2017.

... but HIV/AIDS patient groups want better R&D and think that
greater engagement is key to achieving this goal

Two main themes arising out of HIV/AIDS patient-group comments to the
2017 Corporate-Reputation survey is the wish for pharmaceutical
companies to:

  • actively engage themselves in the communities affected by HIV/AIDS; and
  • create better channels of communication with HIV/AIDS patient groups.

Comments of this nature were made by HIV/AIDS patient groups from all
parts of the world. One compelling reason for such engagement was that
HIV/AIDS patient groups felt themselves well equipped to guide pharma's
R&D activities toward products that people living with HIV/AIDS truly
need.

So, how did the companies perform at corporate reputation in
2017, in the viewpoints of HIV/AIDS patient groups?

Ranking at corporate reputation is measured by patient groups familiar
with a company.

  • ViiV Healthcare ranked overall 1st in 2017 for
    corporate reputation among HIV/AIDS patient groups familiar with the
    company. ViiV has now held this rank for five years in a row. ViiV was
    also 1st in 2017 for eight of the 12 individual indicators of
    corporate reputation.
  • Gilead came next, ranking overall 2nd. The company
    was ranked 1st for four of the 12 indicators of corporate reputation.
  • Janssen was ranked overall 3rd. Janssen also had the
    highest Net Promoter Score (NPS) in the HIV/AIDS element of the 2017
    Corporate-Reputation survey: +33.3%.
  • AbbVie ranked overall 4th. And...
  • GSK, which acts on behalf of ViiV in some geographic
    markets, came 5th.

Key Topics Covered:

  1. Executive Summary
  2. HIV/Aids Patient-Group Relationships With Pharma, 2017
  3. Industry-Wide Findings From HIV/Aids Patient Groups, 2017
  4. Rankings Of The 10 Pharma Companies, 2017 V. 2016
  5. Among HIV/Aids Patient Groups Familiar With The Companies
  6. Positionings Of Seven Pharma Companies, 2017 V. 2016
  7. Among HIV/Aids Patient Groups That Work/Partner With The Companies
  8. Profiles Of The 10 Companies, 2017 
  • Abbvie
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Gilead
  • GSK
  • Janssen
  • Merck & Co/MSD
  • Roche
  • Sanofi
  • ViiV Healthcare

For more information about this report visit https://www.researchandmarkets.com/research/hfztjs/_hivaids_patient?w=4

View Comments and Join the Discussion!